Abstract Body

Presentation:

The biomedical prevention landscape enters a pivotal phase as dapivirine (DPV) vaginal ring progresses beyond Phase III clinical trials. This presentation explores: the role of open-label extension (OLE) studies in refining Phase III results, insights from recent PEPFAR-based data in Zimbabwe on real-world ring use, and the intricate balance required in shaping future target product profiles within a complex regulatory landscape. Topical HIV prevention methods offer not only localized defense but also systemic protection. DPV ring Phase III trials revealed a 30% efficacy point estimate, rising to a promising 50% in women over 21. While pivotal for safety data, OLE studies complement and refine Phase III outcomes. Incorporating real-world scenarios, diverse populations, and long-term observations, these studies provide essential insights for optimizing DPV ring deployment. DPV ring OLE studies found increased counterfactual efficacy estimates. Increased adherence and retention relative to the randomized controlled trials were also noted. WHO’s endorsement propels DPV ring implementation in 11 countries, targeting empowerment for young women, who often face heightened vulnerability due to age-related power dynamics, influencing the cycle of transmission. Favorable views expressed by women in Zimbabwe, underscore the tangible impact of DPV ring implementation. Examining usage patterns, adherence challenges, and demographic factors bridges the gap between clinical trials and practical implementation in resource-limited settings. Additionally, local manufacturing in South Africa aims to reduce ring costs significantly. Navigating a complex regulatory environment, DPV ring demands careful consideration for future target product profiles. Despite Phase III outcomes, studies in adolescents (MTN-034/REACH), pregnant women (MTN-042/DELIVER), and breastfeeding women (MTN-043/B-Protected) affirm safety and acceptability. Emerging 90-day variants and multi-purpose prevention technologies (MPT) underscore the pivotal balance for widespread acceptance and global success. ‘The Ring Comes Full Circle’ represents a crucial juncture in biomedical prevention. Through open-label studies, real-world insights, including vulnerable populations, and a nuanced regulatory approach, we pave the way for effective, user-friendly, and globally applicable interventions. Beyond Phase III perils, DPV ring, with evolving iterations, contributes to our global arsenal against HIV.